IN VITRO FLOW CYTOMETRY METHOD TO QUANTITATIVELY ASSESS INHIBITORS OF P-GLYCOPEPTIDE

ER-JIA WANG, CHRISTOPHER N. CASCIANO, ROBERT P. CLEMENT, AND WILLIAM W. JOHNSON

Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Lafayette, New Jersey

(Received September 8, 1999; accepted January 28, 2000)

This paper is available online at http://www.dmd.org

ABSTRACT:

P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many drugs (Hall et al., 1999). A simple and reliable in vitro method to identify inhibitors of Pgp helps to prevent the potential of drug interactions. Using daunorubicin as a fluorescent marker and vanadate as a positive control compound, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated. Quantitation of the relative fluorescence was used to compare potency of individual inhibitors. Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Cyclosporin A and terfenadine were the most potent inhibitors among the compounds tested. Tetraphenylphosphonium and α-tocopherol had little inhibitory effect. Progesterone produced significant inhibition at relatively high concentrations. This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quantitative tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions.

One of the main obstacles to successful cancer chemotherapy is the development of multiple drug resistance (MDR) to a variety of structurally unrelated cytotoxic drugs. Overexpression of P-glycoprotein (Pgp; 170–180 kDa), the product of the MDR1 gene, is the most commonly observed characteristic of multidrug-resistant cells grown in vitro (Gottesman and Pastan, 1993; Ling, 1995; Schinkel et al., 1995) and in a number of tumors (Redmond et al., 1991; Decker et al., 1995). Pgp, an ATP-dependent multidrug pump belonging to the ABC family of transporters, has been shown to contribute to the resistance of tumor cells to a wide range of structurally unrelated drugs (Horn et al., 1989; Ling, 1995; Gottesman, 1995) and in a number of tumors (Redmond et al., 1991; Decker et al., 1995). These compounds have no common chemical structural features excluding drug interactions. Using daunorubicin as a fluorescent marker and vanadate as a positive control agent, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated. Quantitation of the relative fluorescence was used to compare potency of individual inhibitors. Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Cyclosporin A and terfenadine were the most potent inhibitors among the compounds tested. Tetraphenylphosphonium and α-tocopherol had little inhibitory effect. Progesterone produced significant inhibition at relatively high concentrations. This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quantitative tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions.

One of the main obstacles to successful cancer chemotherapy is the development of multiple drug resistance (MDR) to a variety of structurally unrelated cytotoxic drugs. Overexpression of P-glycoprotein (Pgp; 170–180 kDa), the product of the MDR1 gene, is the most commonly observed characteristic of multidrug-resistant cells grown in vitro (Gottesman and Pastan, 1993; Ling, 1995; Schinkel et al., 1995) and in a number of tumors (Redmond et al., 1991; Decker et al., 1995). Pgp, an ATP-dependent multidrug pump belonging to the ABC family of transporters, has been shown to contribute to the resistance of tumor cells to a wide range of structurally unrelated drugs (Horn et al., 1989; Ling, 1995; Gottesman, 1995) and in a number of tumors (Redmond et al., 1991; Decker et al., 1995). These compounds have no common chemical structural features excluding drug interactions. Using daunorubicin as a fluorescent marker and vanadate as a positive control agent, a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated. Quantitation of the relative fluorescence was used to compare potency of individual inhibitors. Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin. Cyclosporin A and terfenadine were the most potent inhibitors among the compounds tested. Tetraphenylphosphonium and α-tocopherol had little inhibitory effect. Progesterone produced significant inhibition at relatively high concentrations. This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quantitative tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions.
Materials and Methods

Chemicals. DNR, verapamil, vinblastine, colchicine, quinidine, progesterone, gramicidin, nicardipine, α-tocopherol, EGTA, EDTA, TRIZMA base, HEPES, and cyclosporin A were purchased from Sigma Chemical Co. (St. Louis, MO). Hanks’ balanced salt solution, α-minimum essential medium (α-MEM), Dulbecco’s modified Eagle’s medium, penicillin/streptomycin, fetal bovine serum (FBS), and trypsin-EDTA were obtained from Life Technologies, Inc. (Rockville, MD). Sodium orthovanadate was purchased from Pfaltz & Bauer Inc. (Waterbury, CT). Tetrakis[pentafluorophenyl]porphyrin (TPP) was obtained from Aldrich Chemical Co. (Milwaukee, WI). Microplates (Costar 96-well), plastic tubes, and cell culture flasks (75 cm²) were purchased from Corning.

Results

Fig. 1. Intracellular retention of DNR from multidrug-resistant CR1R12 cells in the presence of 0.1 μM DNR (a), 1 μM DNR (b), and 5 μM DNR (c).

Cells were treated as described in Materials and Methods before the flow cytometry analysis. Histograms represent the cell counter numbers versus fluorescent intensity expressed as log relative fluorescence. In each figure, four overlaid histograms represent, from left to right, the peak from autofluorescent control cells without DNR (No DNR), the peak from 30-min efflux cells (Eff), the peak from 30-min accumulation cells (Acc), and the peak from cells coincubated with 1 μM verapamil (Ver). The geometric means of fluorescent intensity for No DNR, Eff, Acc, and Ver are 22.54, 23.52, 27.11, and 40.88, respectively, in 1a; 22.54, 59.44, 108.98, and 218.74, respectively, in 1b; and 22.54, 251.00, 513.15, and 1104.05, respectively, in 1c.

Fig. 2. Effect of verapamil (0–100 μM) on intracellular retention of DNR in CR1R12 cells either in the accumulation phase (a) and/or in the efflux phase (b).

Histograms represent the cell counter numbers versus fluorescent intensity expressed as log relative fluorescence. The geometric means of fluorescent intensity for No DNR, 0, 10, 20, and 100 μM verapamil are 29.22, 459.91, 1738.99, 2986.73 and 4692.86, respectively, in 2a; for No DNR, 0, 2, 10, 20, and 100 μM are 29.22, 98.19, 144.83, 586.59, 1602.54, and 3324.83, respectively, in 2b.

Fig. 3. Effect of vanadate on intracellular retention of DNR in CR1R12 cells.

Graph represents fluorescent intensity expressed as relative fluorescence (% inhibition) versus concentrations of vanadate.
Intracellular retention of DNR in CR1R12 cells in the accumulation phase (a) and in the efflux phase (b).

Fig. 4. Intracellular retention of DNR in CR1R12 cells in the accumulation phase (a) and in the efflux phase (b).

Inc. (Corning, NY). All other reagents were of the highest grade commercially available.

Tumor Cells. CR1R12 cell line, provided by Dr. Alan Senior (University of Rochester, Rochester, NY), was maintained in complete α-MEM supplemented with 10% FBS, penicillin/streptomycin 50 U/50 μg/ml in a 5% CO₂/95% air atmosphere at 37°C. Colchicine (0.5 μg/ml) was added to the culture medium. Cells were grown to 80 to 90% confluency and treated with trypsin-EDTA before subculturing.

Fluorescence-Activated Cell Sorter (FACS) Flow Cytometry. Fluorescence measurements of individual cells were performed with a Becton-Dickinson FACScalibur (San Jose, CA) equipped with a ultraviolet argon laser (excitation at 488 nm, emission at 530/30 and 570/30 nm band-pass filters). Analysis was gated to include single cells on the basis of forward and side light-scatter and was based on acquisition of data from 10,000 cells. Log fluorescence was collected and displayed as single parameter histograms.

A direct functional assay for the Pgp efflux pump in CR1R12 cells was performed with the flow cytometer. When DNR, a fluorescent substrate, is diffused into the cell, Pgp actively pumps out the fluorochrome. If another compound that is a substrate and/or inhibitor is present in the same manner along with the fluorescence marker, the fluorescent marker accumulates in the cell, resulting in a higher intensity of fluorescence. Compounds that impede the efflux of the fluorescent substrate markers can thus be quantitatively analyzed and compared with respect to their potency to inhibit the Pgp efflux pump.

Cell Incubation Assays. On the day of the experiment, the cell media was replaced with fresh 10% FBS α-MEM containing no Pgp inducers 60 min before cell detachment with trypsin-EDTA. Cells with 80 to 90% confluency were routinely used for the transport studies. After the media was removed, trypsin-EDTA was used to detach the cells from the plates. The cells were centrifuged (50g for 3 min) at room temperature and resuspended in 10% FBS α-MEM at a concentration of 6,000,000 cells/ml. Aliquots (50 μl) of the cell suspension were transferred to plastic tubes containing 1.95 ml of incubation media containing DNR. In the accumulation phase, cells were incubated in the presence or absence of test drugs in 10% FBS α-MEM with 0.1 to 5 μM DNR for 30 min at 37°C. After centrifugation (50g for 3 min at 4°C) and removal of supernatant, the cells were reincubated in 10% FBS α-MEM in the presence or absence of modulators without DNR for an additional 30 min at 37°C (the efflux phase). After final centrifugation (50g for 3 min at 4°C), the supernatant was removed. Cold Hanks’ buffer was then added to each tube, and the cell suspension was transferred to FACS tubes, which were placed on ice (less than 1 h) until analysis.

Cell Viability Test. Cell viability was tested with 0.4% trypan blue and then propidium iodide staining. Dead cells in which propidium iodide was bound to double strands of DNA or RNA were detected in certain regions of cytometry dot plots and were not included in the final data calculations.

Calculation of Relative Fluorescence Channel Numbers. The DNR fluorescence intensities of individual cells are recorded as histograms. The mean fluorescence intensity of 10,000 cells is used for comparison among different conditions. Vanadate was selected as a positive control and standard compound because it can maximally inactivate the Pgp efflux pump. Figure 3 shows vanadate (5 mM) reaching maximal geometric mean fluorescence for DNR retention. This concentration was therefore used in each set of experiments. Relative fluorescence was used for quantitation and comparison between different compounds. The relative fluorescence (percent inactivation) represents a ratio obtained through the following formula: the geometric mean (because the data is acquired as a logarithm) fluorescence of a discrete sample divided by the geometric mean fluorescence in the presence of 5 mM vanadate, times 100 or expressed as:

Relative fluorescence = \frac{\text{Fluorescence of sample geometric mean}}{\text{Fluorescence of vanadate geometric mean}} \times 100

The denominator represents inactivation or complete preclusion of the function of Pgp active efflux. The numerator is the resulting signal caused by test compound inhibiting the function of Pgp active efflux. Therefore, this ratio is a factor that normalizes the degree of inhibition by the compound relative to the total absence of Pgp function and allows for normalization of the results across sample sets.

Results

DNR Dose-Dependent Fluorescence Intensity in CR1R12 Cells. Three concentrations (0.1, 1, and 5 μM) of DNR were tested in viable CR1R12 cells for their fluorescence intensity at the end of a 30-min accumulation phase, at the end of a 30-min efflux phase, and at the end of a 30-min efflux phase with 1 μM verapamil. When a DNR concentration of 0.1 μM was incubated with the CR1R12 cells in media (Fig. 1a), there was a marked difference between the accumulation and efflux phases. The geometric means of fluorescent intensity for efflux, accumulation, and verapamil are 59, 109, and 219 in 1b, respectively. The separation was even greater at 5 μM DNR (Fig. 1c). These results indicated that a concentration of between 1 and 5 μM DNR provides reasonable fluorescence to distinguish differences, thereby making this range suitable for additional inhibition studies. Additionally, this indicates that as much as 5 μM was not cytotoxic over the duration of the experiment based on the ability of the cell to retain DNR. However, to avoid potential cytotoxic effects, a concentration of 2 μM was considered optimal. This is very conservative as the ED₅₀ for DNR is 26.5 μM in this MDR cell line (Al-Shawi and Senior, 1993; The ED₅₀ is the concentration of drug required to reduce colony formation to 50% of that observed in the absence of the drug.).

Comparison of Effects of Drug Influx and Efflux. When DNR, a Pgp substrate, was coincubated with a Pgp inhibitor or test compound in the cell culture, the test compound might interact with Pgp and affect transport of DNR. During the accumulation phase, the concentration of DNR is higher outside the cell. Because the passive diffusion of DNR into cells and the Pgp-mediated efflux are in opposite directions, the inhibition of the Pgp pump caused a relative increase in DNR levels within the cells. In the efflux phase, the concentration of DNR is lower outside the cell, and thus the direction of the passive diffusion and the Pgp-mediated efflux is the same. When the Pgp...
Fig. 5. Effect of drugs or chemicals on intracellular retention of DNR in CR1IR12 cells.

Graphs showing fluorescent intensity expressed as relative fluorescence (% inhibition) in the presence of different concentrations of inhibitors.
pump is inhibited in the efflux phase, DNR exits the cell primarily by passive diffusion. As a result, DNR retention in the efflux phase (Fig. 2b) was lower compared with that in the accumulation phase (Fig. 2a) at given concentrations of verapamil. Increasing concentrations of verapamil caused a concentration-dependent increase in fluorescent intensity in both the accumulation and efflux phases with slightly greater separation during the efflux phase. Although DNR and verapamil are known to be substrates of the Pgp efflux enzyme, a nonPgp substrate fluorescent indicator was used to further test for a nonspecific effect on DNR retention by verapamil and the other test compounds. The presence of saturating inhibition concentrations (see below) of cyclosporin A (50 μM), quinidine (100 μM), verapamil (100 μM), ketoconazole (100 μM), terfenadine (25 μM), progesterone (500 μM), had no detectable effect on the retention of resorufin fluorescence, which has similar fluorescence qualities as DNR (data not shown).

### Effects of Vanadate on Accumulation of DNR in CR1R12 Cells.
Vanadate is a competitive inhibitor of the Pgp-ATPase at the ATP binding site and, therefore, is distinct from other MDR1 transport site inhibitors. As shown in Fig. 3, vanadate caused a concentration-dependent increase in DNR retention in CR1R12 cells. Vanadate concentrations less than 100 μM had little effect on DNR retention. However, vanadate concentrations between 100 and 12,000 μM produced a sigmoidal DNR retention response curve, with maximal accumulation at ~5 mM.

### Time Dependence of DNR Influx and Efflux in CR1R12 Cells.
DNR diffused into CR1R12 cells very rapidly. Within 2 to 5 min, the accumulation of DNR reached a plateau as shown in Fig. 4a. To assure maximal retention of DNR, subsequent experiments were allowed to incubate for 30 min. During the efflux phase (Fig. 4b), the time required to reach steady state with respect to DNR was between 10 and 15 min. For most of the assays, 30 min were allowed for DNR efflux.

### Potency and Efficacy of Known Pgp Inhibitors on DNR Efflux.
To examine the inhibition of the efflux of DNR via Pgp, a number of potential inhibitors were tested (Fig. 5, a–l). The efflux inhibition potency of each compound was compared with that of vanadate. In general, all compounds tested demonstrated only partial inhibition of efflux. Increasing the concentration of most inhibitors increased the intracellular retention of DNR. After reaching a point of maximal inhibition, the inhibitory effect decreased dramatically for most compounds at higher concentrations. For a limited number of compounds, a stable plateau was achieved at higher concentrations (verapamil, for example). Cyclosporin A and progesterone (Fig. 5, f and h) produced a significant inhibition, which was approximately 75 and 60% of that observed with vanadate, respectively. Verapamil and terfenadine produced 40 to 50% inhibition relative to vanadate (Fig. 5, e and c). Vinblastine, quinidine, tamoxifen, and nicardipine produced 30 to 40% relative inhibition (Fig. 5, a, b, d, and i). Gramicidin (Fig. 5j) had a slight inhibitory effect (14%), and TPP and α-tocopherol (Fig. 5, k and l) had no significant inhibitory effect on DNR efflux.

### Discussion
To be suitable for a functional flow cytometry assay, a Pgp marker must satisfy several criteria: 1) it should be primarily transported by the Pgp pump; 2) it should be a good fluorescent marker, and 3) its rate of passive diffusion should be slow compared with the rate of Pgp-mediated active transport. In earlier drug efflux functional assays, DNR was used for determination of cellular drug retention (Krishan and Ganapathi, 1980; Nooter et al., 1983; Krishan et al., 1987; Ross et al., 1995; Baggetto et al., 1998) and for evaluation of Pgp phenotypes in clinical samples (Chin-Yee et al., 1994; Maynadie et al.,...
with respect to inhibition of the Pgp transporter, the combination of the accumulation and efflux assays is desirable.

Use of cell lines expressing different levels of Pgp may result in differences in the potency determined for related inhibitors. Quantitative values such as IC_{50} from CR1R12 cells could not be directly compared with those from other cell lines. When compounds are tested in the same cell system for the purpose of comparison, it is important to assess the relative potency of the inhibitors. This study demonstrates that most of the known MDR inhibitors are partial inhibitors of DNR efflux. Exposure to quinidine, nicardipine, vinblastine, and tamoxifen resulted in 33% inhibition of DNR efflux activity. Terfenadine and verapamil blocked 42% of DNR efflux. In contrast to previous reports, which indicated that TPP and α-tocopherol were Pgp modulators (Gros et al., 1992; Relling, 1996; Hall et al., 1999), these studies demonstrated that these compounds do not significantly affect the efflux of DNR. Among compounds tested to date, only cyclosporin A and progesterone achieved greater than 50% inhibition. Most of the inhibitors did not reach a level of 50% inhibition, and the effective concentrations were in the micromolar range. This may explain the limited clinical significance when these inhibitors are used in combination chemotherapy.

In conclusion, this study provides an improved method for assessing the potency of a candidate drug to inhibit the Pgp-mediated efflux pump. With DNR as a fluorescent marker and vanadate as a positive control compound, most known Pgp inhibitors were classified as partial, low potency antagonists. A significant improvement in chemotherapy may need to include a search for more potent Pgp inhibitors.

References


